Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
Metal Oxide Nanomaterials Metal-based NMs have the advantages of low detection limits, high D/I efficiency, and relatively simple sample preparation
Available at: Singh, P., et al
Is Pepta Labs a Peptide Sciences alternative for 5-Amino-1MQ 50mg
This hormone helps control reproduction
In addition, there is ample evidence demonstrating that the accumulation of cellular ceramides is associated with the pathogenesis of diseases such as obesity, diabetes, atherosclerosis, and cardiomyopathy